Evidence map›Paper›PMID 26451111›Full record

ReviewInternational journal of nanomedicine2015

Natural product-based nanomedicine: recent advances and issues.

Rebekah Watkins, Ling Wu, Chenming Zhang, Richey M Davis, Bin Xu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
135citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

135 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Frontiers in oncology · 2021
    Pooled it
  3. Article
  4. Meroterpenoids and Fucoxanthin from the Brown SeaweedMolecules (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Polyphenol-RichPharmaceutics · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

75 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Rebekah WatkinsDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Program in Nanoscience, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Ling WuDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Chenming ZhangCenter for Drug Discovery, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Department of Biological Systems Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Institute for Critical Technology and Applied Science, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Richey M DavisCenter for Drug Discovery, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Institute for Critical Technology and Applied Science, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Department of Chemical Engineering, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.
Bin XuDepartment of Biochemistry, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA ; Center for Drug Discovery, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products have been used in medicine for many years. Many top-selling pharmaceuticals are natural compounds or their derivatives. These plant- or microorganism-derived compounds have shown potential as therapeutic agents against cancer, microbial infection, inflammation, and other disease conditions. However, their success in clinical trials has been less impressive, partly due to the compounds' low bioavailability. The incorporation of nanoparticles into a delivery system for natural products would be a major advance in the efforts to increase their therapeutic effects. Recently, advances have been made showing that nanoparticles can significantly increase the bioavailability of natural products both in vitro and in vivo. Nanotechnology has demonstrated its capability to manipulate particles in order to target specific areas of the body and control the release of drugs. Although there are many benefits to applying nanotechnology for better delivery of natural products, it is not without issues. Drug targeting remains a challenge and potential nanoparticle toxicity needs to be further investigated, especially if these systems are to be used to treat chronic human diseases. This review aims to summarize recent progress in several key areas relevant to natural products in nanoparticle delivery systems for biomedical applications.

Indexed as

Biological ProductsHumansNanomedicineNanoparticlesNeoplasmsBiological Productsbioavailabilitycontrolled releasedrug deliverynanomedicinenatural productstargeting

Identifiers

PMID26451111
PMCPMC4592057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.